Study Reveals Impact of Immunosuppression on Sinonasal Conditions in Transplant Patients
A recent study highlights significant differences in sinonasal disease rates among kidney and liver transplant recipients based on their immunosuppression regimens.
Basiliximab linked to higher rates of allergic rhinitis and fungal sinusitis compared to ATG.
Tacrolimus-based maintenance therapy shows increased rates of allergic rhinitis and acute invasive fungal sinusitis over cyclosporine.
The study analyzed data from over 106 healthcare organizations in the U.S. from 2010 to 2025.
A comprehensive study has found that the choice of immunosuppression regimens significantly affects sinonasal disease outcomes in adults undergoing kidney and liver transplants. Conducted across multiple centers, the research utilized data from the TriNetX database, which encompasses 106 healthcare organizations in the United States, covering the period from January 1, 2010, to July 31, 2025.
The study focused on comparing two induction therapies: basiliximab and anti-thymocyte globulin (ATG). It was observed that patients receiving basiliximab experienced notably higher rates of allergic rhinitis, chronic rhinosinusitis with nasal polyposis, and acute invasive fungal sinusitis compared to those treated with ATG. Specifically, the relative risks reported were 0.89 for allergic rhinitis, 0.62 for chronic rhinosinusitis with nasal polyposis, and 0.43 for acute invasive fungal sinusitis, indicating a concerning trend for patients on basiliximab.
In terms of maintenance therapy, tacrolimus was associated with increased rates of allergic rhinitis and acute invasive fungal sinusitis compared to cyclosporine, with relative risks of 1.29 for allergic rhinitis and 1.73 for acute invasive fungal sinusitis. However, rates of surgical interventions for chronic rhinosinusitis were similar between the two treatment groups, suggesting that while initial treatment regimens may influence disease rates, surgical outcomes might not differ significantly.
The implications of these findings are substantial for transplant recipients and healthcare providers. The study suggests that the selection of immunosuppression regimens can lead to varying sinonasal disease outcomes, which may affect the quality of life and overall health of patients. As such, clinicians may need to consider these risks when determining the best immunosuppression strategy for their patients.
Looking ahead, further research is warranted to explore the long-term implications of these findings and to refine immunosuppression protocols. The study's authors emphasize the need for ongoing monitoring of sinonasal health in transplant patients to mitigate potential complications associated with their treatment regimens.
